Increasing percentages of some older U.S. men with intermediate-risk and high-risk prostate cancers are undergoing treatments that carry risks of side effects that can significantly reduce the quality of life without extending life, according to a new study led by Cedars-Sinai.
Covid biotech’s stock jumps after positive early PhIII monoclonal antibody data reveal
Invivyd on Monday reported positive early Phase III data for its monoclonal antibody designed to prevent symptomatic Covid-19 among immunocompromised individuals, triggering the biotech’s stock